Head-to-head · Cost-Efficiency Index
Invigor Medical vs GoodRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalGoodRx
Cost-first shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Visit GoodRxThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 72. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. GoodRx still earns a C — Cost-first shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | GoodRx |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 72/100 |
| Semaglutide / mo | $199/mo | Not disclosed |
| Tirzepatide / mo | $339/mo | $299/mo (brand Zepbound) |
| Semaglutide / yr (modeled) | $2,388 | — |
| Tirzepatide / yr (modeled) | $4,068 | $3,588 |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #8 | #78 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
GoodRx
72/100Where the value is
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
The tradeoffs
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.